IND 19 - The Future is Now: The Novel GBCA Gadopiclenol

Gadolinium-based contrast agents (GBCAs) are fundamental to many diagnostic MRI procedures. However, until recently, most purely extracellular GBCAs had similar relaxivity properties resulting in similar contrast enhancement when administered at equivalent dose. Gadopiclenol is a newly approved, highly stable GBCA with markedly increased relaxivity which permits the administered dose to be halved relative to the approved dose of most other extracellular GBCAs without loss of diagnostic performance. This symposium will address the importance of high relaxivity in clinical practice and will present early clinical experience with gadopiclenol for approved indications in the body and CNS.